May 29, 2020
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
May 13, 2020
Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
May 13, 2020
Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
May 05, 2020
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
Apr 27, 2020
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
Jan 16, 2020
Libtayo(TM) (cemiplimab) Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Dec 18, 2019
Quantum Leap Healthcare Collaborative Announces the Selection of Regeneron's Libtayo® (cemiplimab) and REGN3767 for Injection in the I-SPY 2 TRIAL for Breast Cancer
Nov 06, 2019
Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting
Nov 06, 2019
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
Jun 06, 2019
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
May 16, 2019
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
May 15, 2019
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
Jan 24, 2019
Cutaneous Squamous Cell Carcinoma (cSCC) Market Insights, Epidemiology and Market Forecasts, 2016-2018 & 2027